Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)

Kuzman, Ilija and Bezlepko, Alexandr and Kondova Topuzovska, Irena and Rókusz, László and Iudina, Liudmyla and Marschall, Hans-Peter and Petri, Thomas (2014) Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC Pulmonary Medicine, 14. p. 105. ISSN 1471-2466

[img] PDF - Published Version
Download (455kB)


BACKGROUND: Community acquired pneumonia (CAP) is a major cause of morbidity, hospitalization, and mortality worldwide. Management of CAP for many patients requires rapid initiation of empirical antibiotic treatment, based on the spectrum of activity of available antimicrobial agents and evidence on local antibiotic resistance. Few data exist on the severity profile and treatment of hospitalized CAP patients in Eastern and Central Europe and the Middle East, in particular on use of moxifloxacin (Avelox®), which is approved in these regions. ----- METHODS: CAPRIVI (Community Acquired Pneumonia: tReatment wIth AVelox® in hospItalized patients) was a prospective observational study in 12 countries: Croatia, France, Hungary, Kazakhstan, Jordan, Kyrgyzstan, Lebanon, Republic of Moldova, Romania, Russia, Ukraine, and Macedonia. Patients aged >18 years were treated with moxifloxacin 400 mg daily following hospitalization with a CAP diagnosis. In addition to efficacy and safety outcomes, data were collected on patient history and disease severity measured by CRB-65 score. ----- RESULTS: 2733 patients were enrolled. A low severity index (i.e., CRB-65 score <2) was reported in 87.5% of CAP patients assessed (n=1847), an unexpectedly high proportion for hospitalized patients. Moxifloxacin administered for a mean of 10.0 days (range: 2.0 to 39.0 days) was highly effective: 96.7% of patients in the efficacy population (n=2152) improved and 93.2% were cured of infection during the study. Severity of infection changed from "moderate" or "severe" in 91.8% of patients at baseline to "no infection" or "mild" in 95.5% at last visit. In the safety population (n=2595), 127 (4.9%) patients had treatment-emergent adverse events (TEAEs) and 40 (1.54%) patients had serious TEAEs; none of these 40 patients died. The safety results were consistent with the known profile of moxifloxacin. ----- CONCLUSIONS: The efficacy and safety profiles of moxifloxacin at the recommended dose of 400 mg daily are characterized in this large observational study of hospitalized CAP patients from Eastern and Central Europe and the Middle East. The high response rate in this study, which included patients with a range of disease severities, suggests that treatment with broader-spectrum drugs such as moxifloxacin is appropriate for patients with CAP who are managed in hospital.

Item Type: Article
Additional Information: © Kuzman et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0​) applies to the data made available in this article, unless otherwise stated.
MeSH: Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/therapeutic use ; Community-Acquired Infections/diagnosis ; Community-Acquired Infections/drug therapy ; Europe, Eastern ; Female ; Fluoroquinolones/adverse effects ; Fluoroquinolones/therapeutic use ; France ; Hospitalization ; Humans ; Kazakhstan ; Kyrgyzstan ; Length of Stay ; Male ; Middle Aged ; Middle East ; Pneumonia/diagnosis ; Pneumonia/drug therapy ; Prospective Studies ; Severity of Illness Index ; Young Adult
Departments: Katedra za infektologiju
Depositing User: Marijan Šember
Status: Published
Bezlepko, AlexandrUNSPECIFIED
Kondova Topuzovska, IrenaUNSPECIFIED
Iudina, LiudmylaUNSPECIFIED
Marschall, Hans-PeterUNSPECIFIED
Date: 30 June 2014
Date Deposited: 18 Feb 2016 12:00
Last Modified: 17 Jul 2020 08:36
Subjects: /
Related URLs:
URI: http://medlib.mef.hr/id/eprint/2463

Actions (login required)

View Item View Item


Downloads per month over past year